A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
عنوان الدراسة
ational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
داعم الدراسة
Astrazeneca
دواء الدراسة
Ultomiris (Ravulizumab)
رقم بروتوكول الدراسة
ALX-NMO-50
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh) ,King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
4
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.